shph logo wire.jpg
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
19 déc. 2024 09h00 HE | Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Candel_Logo_FullColor (4).png
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
16 déc. 2024 16h01 HE | Candel Therapeutics
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Candel_Logo_FullColor (4).png
Candel Therapeutics Announces Pricing of Public Offering
12 déc. 2024 23h00 HE | Candel Therapeutics
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Candel_Logo_FullColor (4).png
Candel Therapeutics Announces $80 Million Proposed Public Offering
12 déc. 2024 16h51 HE | Candel Therapeutics
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
myriad_S_stacked.png
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
10 déc. 2024 08h00 HE | Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
myriad_S_stacked.png
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
09 déc. 2024 08h00 HE | Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
Asia-Pacific Radiation Oncology Market
Asia-Pacific Radiation Oncology Market Analysis Report 2025-2030 - External Beam Radiation Therapy (EBRT) Dominated the Market with a Revenue Share of 35.9% in 2024
26 nov. 2024 05h18 HE | Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Radiation Oncology Market Size, Share & Trends Analysis Report by Type (External Beam Radiation Therapy, Internal Beam Radiation...
Straits Logo 1-01 (1).png
Liquid Biopsy Market Size to Worth USD 28.84 Billion by 2033 | Straits Research New York, United States, Nov. 21, 2024 (GLOBE NEWSWIRE) -- "Liquid biopsy" isolates and detects circulating nucleic acids (DNA or RNA), exosomes, and circulating tumor cells to diagnose primary...
Koelis software fusion interface using 3D ultrasound for transperineal guidance in prostate cancer focal therapy
KOELIS announces the first interim results of the VIOLETTE trial which evaluates the use of OBT-Fusion® technology in focal ablation of the prostate by microwave needles
20 nov. 2024 09h00 HE | Koelis
GRENOBLE, France, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today passing an important...
Picture1.jpg
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
19 nov. 2024 03h30 HE | Curium
ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...